Quince Therapeutics (NASDAQ:QNCX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09), Zacks reports. The company had revenue of $0.17 million during the quarter.
Quince Therapeutics Stock Performance
Shares of QNCX opened at $1.40 on Tuesday. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The stock has a market capitalization of $61.60 million, a PE ratio of -1.13 and a beta of 0.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.44.
Analyst Ratings Changes
QNCX has been the topic of a number of research analyst reports. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target on the stock. D. Boral Capital restated a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a report on Wednesday, February 5th. Finally, Oppenheimer assumed coverage on Quince Therapeutics in a research note on Monday. They set an “outperform” rating and a $10.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Quince Therapeutics has an average rating of “Buy” and an average target price of $9.60.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Read More
- Five stocks we like better than Quince Therapeutics
- How to Find Undervalued Stocks
- Small-Caps, Big Buybacks: 3 Stocks With Large Buyback Capacity
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Boeing Breaks Out: What the Market Is Signaling Now
- How to Use the MarketBeat Excel Dividend Calculator
- Quantum Gamble? Is IonQ’s Stock an Opportunity or a Mirage?
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
